Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New biopsy technique may boost sarcoidosis diagnosis rates

NCT ID NCT05374447

Diagnosis Sponsor: George Washington University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a tiny forceps biopsy to the standard needle biopsy during a lung ultrasound procedure helps doctors diagnose sarcoidosis more often. Fifty-five adults with enlarged lymph nodes in the chest took part. The goal was to see if the combined approach gives a clearer diagnosis than the needle alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Jun 2022

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Radiologic evidence of mediastinal and/or hilar lymphadenopathy * Attending radiologist or pulmonologist reports a possible diagnosis of sarcoidosis * Age 18 years or older Exclusion Criteria\*: These are the characteristics that a participant must NOT have in order to be eligible to participate in the study. Order Number Criteria * Severe pulmonary hypertension * Inability to undergo general anesthesia * Severe coagulopathy or bleeding diathesis * Previously diagnosed sarcoidosis * Patient presently taking clopidogrel * Patient deemed to be high risk for general anesthesia per anesthesiologist * Hemodynamic instability * Mediastinitis * Acute Hypercarbic Respiratory Failure (pCO2 \>55mmHg)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mediastinal diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Mediastinal Diseases pulmonary sarcoidosis sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mediastinal diseases Mediastinal lymphadenopathy Sarcoidosis, pulmonary

Contacts and locations

Locations

  • The George Washington University Hospital

    Washington D.C., District of Columbia, 20037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.